INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 446m ago
HOUSE PTR46m ago
SEC 13F46m ago
ROBINHOOD CHAIN45m ago
SEC FORM 4/Grant or awardVerified data

Lawver Teri L reported ALT

Director · Altimmune, Inc. · Altimmune, Inc. — Stock Options (option to buy)

Side
A
Value
—
Shares
48.8K
Price
—
Executed
May 1, 2026
Disclosed
May 1, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
May 1 executedMay 1, 2026 disclosed

ALT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ALT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    GP
    Greenleaf PeterDirector
    ALTAltimmune, Inc.
    Grant or award
    		A—
    160.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    HG
    Howarth Alex G.Director
    ALTAltimmune, Inc.
    Grant or award
    		A—
    160.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MT
    Menziuso Richard ThomasPrincipal Accounting Officer
    ALTAltimmune, Inc.
    Grant or award
    		A—
    84.5K sh
    		Oct 1, 2026Oct 2, 2026
    traded Oct 1, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MT
    Menziuso Richard ThomasPrincipal Accounting Officer
    ALTAltimmune, Inc.
    Grant or award
    		A—
    36.2K sh
    		Oct 1, 2026Oct 2, 2026
    traded Oct 1, 2026
    		+1dSEC FORM 4

    Evidence

    33
    DB
    Durso Jerome BenedictDirector, President and CEO
    ALTAltimmune, Inc.
    Open-market purchase
    		BUY$44K
    15.0K sh
    		Aug 13, 2026Aug 13, 2026
    traded Aug 13, 2026
    		+0dSEC FORM 4

    Evidence

    13
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Grant or award
    		A$14K
    4,571 sh
    		Jan 31, 2026Feb 2, 2026
    traded Jan 31, 2026
    		+2dSEC FORM 4

    Evidence

    21
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    15.8K sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    17
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    15.8K sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    13
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Tax withholding
    		F$26K
    4,229 sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    15.8K sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Tax withholding
    		F$29K
    4,748 sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    21
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    15.8K sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Tax withholding
    		F$24K
    4,373 sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    21
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    14.6K sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    17
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    14.6K sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    13
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Tax withholding
    		F$21K
    3,855 sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    21
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    14.6K sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    14.6K sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    41
    PW
    Pisano WayneDirector
    ALTAltimmune, Inc.
    Open-market purchase
    		BUY$20K
    5,000 sh
    		Jan 8, 2026Jan 9, 2026
    traded Jan 8, 2026
    		+1dSEC FORM 4

    Evidence

    44
    DB
    Durso Jerome BenedictDirector
    ALTAltimmune, Inc.
    Open-market purchase
    		BUY$52K
    12.5K sh
    		Dec 22, 2025Dec 22, 2025
    traded Dec 22, 2025
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001960596-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 1, 2026
    Published
    May 1, 2026
    Ingested by INSIDER
    Nov 5, 04:01 UTC
    Last re-read
    Nov 5, 04:01 UTC

    Extracted facts

    Filer
    Lawver Teri L
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Altimmune, Inc. — Stock Options (option to buy)
    Ticker
    ALT
    Shares
    48.8K
    Price per share
    $0
    Execution date (reported)
    May 1, 2026
    Owned after transaction
    48.8K shares
    Days from execution to publication
    0

    What this establishes

    Lawver Teri L filed this Form 4 reporting a grant or award of ALT on May 1, 2026. It became public on May 1, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Lawver Teri Lcik:0001960596
    Issuer
    Altimmune, Inc.cik:0001326190

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.